Table 3 Clinical trials evaluating biomarkers of response in HCC patients treated by immunotherapy
From: Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma
Identifier No. | Biomarker type | Treatment | Patients |
|---|---|---|---|
Circulating Immune Cells | Atezolizumab/Bevacizumab | Advanced HCC | |
NCT04965454 (ExTRACT-HCC) | Genomic liquid biopsy based biomarkers | ICIs | Inoperable HCC |
Not specified | Lenvatinib plus Pembrolizumab | Advanced hepatobiliary tumors | |
NCT04642664 (ACABC) | Not specified | Apatinib plus Camrelizumab | Hepatobiliary Neoplasm |
NCT03595813 (IMMUNO-SUP) | Plasma immunosuppressive actors | ICIs | Locally advanced or metastatic solid tumor |
NCT03514368 (MINER) | Immunological biomarkers from blood samples | ICIs, alone or in combination | Any advanced solid tumor |